ACRS (Aclaris Therapeutics) Short-Term Debt to Capital

The price action of Aclaris Therapeutics (ACRS) reflects the financial standing of a business whose revenues will be based on the market launch of immunological agents against alopecia and skin inflammation. Aclaris Therapeutics (ACRS) is developing therapies to combat psoriasis and dermatological pathologies, reaching the value of 0.00. The company is currently testing its developments, meaning high research costs are temporarily reducing investment efficiency and limiting profit growth.

This ratio determines the company's dependence on current liabilities by comparing loans with a maturity of up to one year against the volume of equity. An increase in this metric signals liquidity risk, whereas a decrease may indicate an underutilization of financial leverage. By analyzing the change in short-term debt-to-equity, an investor assesses balance sheet stability. For Aclaris Therapeutics (ACRS), this is critical when financing long-term clinical trials that require physician participation.